Bolt Biotherapeutics, Inc. (BOLT): Submission of Matters to a Vote of Security Holders
Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001641281 0001641281 2025-05-27 2025-05-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,
How this was made
The 30-second read
Why it matters
The disclosure confirms (1) two Class II director nominees were elected and (2) PricewaterhouseCoopers LLP was ratified as independent registered public accounting firm for the year ending December 31, 2026.
Market read
Routine annual meeting results; no new clinical, regulatory, or financial guidance information is provided in the text.
What to watch
Traders should check whether the referenced April 28, 2026 proxy (Schedule 14A) contains any substantive changes (e.g., compensation, proposals) not captured in this 8-K excerpt.
Background
The company held its 2026 annual stockholders meeting on June 10, 2026 and reported the voting outcomes via SEC Form 8-K (Item 5.07).
Ticker impact
Bolt Biotherapeutics filed an 8-K confirming director nominees were elected and PwC ratified as independent auditor for 2026.
Low likelihood of a sustained price move; any reaction is likely muted unless tied to other concurrent events not included here.
The filing reports voting results (board election and auditor ratification) without new financial guidance, clinical/regulatory updates, or material transactions.
Market effects
Minimal; governance/auditor ratification does not change biotech sector risk factors.
Minimal; company-specific corporate action only.
Minimal; no cross-border deal, regulator action, or supply-chain event described.
Counterpoint
If investors were concerned about governance/auditor continuity, the ratification could reduce perceived risk, but the article provides no evidence of such a dispute.
Key entities
- issuerBolt Biotherapeutics, Inc.
Nasdaq-listed biotech company filing the 8-K with annual meeting voting results.
- auditorPricewaterhouseCoopers LLP
Ratified as independent registered public accounting firm for 2026.
- executiveWilliam P. Quinn
CEO/CFO signing the 8-K.
